Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4073)	4/16/1998 12:53:00 PM
From: Steve Fancy	Read Replies (1) \| Respond to of 6136

Although analysts miss all the time, FWIW, I think Doug Lind was the big AGPH fan initially from PW. Ms Wang picked up the ball at PW after he left. I believe PW has maintained the $70 - $75 price target going back to mid-96. I know that PW is a marketmaker in the stock. That's a good analyst trick...if you maintain a price target for enough years, you have a 50-50 chance somewhere along the line. Keep in mind the date referred to in this post is 2/27/97. exchange2000.com

To: Steve Fancy who wrote (4073)	4/16/1998 7:23:00 PM
From: Paul Barr	Read Replies (4) \| Respond to of 6136

Steve: Sell your stock and move on. I am tired of your complaining. This company has exceeded everyone's expectations. They know exactly what they are doing and where they are selling product. They keep beating estimates and you make a stupid statement like that. I am sure you thought that VIRACEPT would be this successful when it was first approved. Yeah, right!!! Just sell your position and find another biotech company whose first drug will have $500 million in first year sales.